Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

14,904 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The influence of hepatitis B DNA level and antiviral therapy on recurrence after initial curative treatment in patients with hepatocellular carcinoma.
Chuma M, Hige S, Kamiyama T, Meguro T, Nagasaka A, Nakanishi K, Yamamoto Y, Nakanishi M, Kohara T, Sho T, Yamamoto K, Horimoto H, Kobayashi T, Yokoo H, Matsushita M, Todo S, Asaka M. Chuma M, et al. Among authors: kobayashi t. J Gastroenterol. 2009;44(9):991-9. doi: 10.1007/s00535-009-0093-z. Epub 2009 Jun 25. J Gastroenterol. 2009. PMID: 19554391 Free article.
Efficacy of therapy for advanced hepatocellular carcinoma: intra-arterial 5-fluorouracil and subcutaneous interferon with image-guided radiation.
Chuma M, Taguchi H, Yamamoto Y, Shimizu S, Nakanishi M, Ogawa K, Sho T, Horimoto H, Kobayashi T, Nakai M, Terashita K, Sakuhara Y, Abo D, Tsukuda Y, Tsunematsu S, Hige S, Kato M, Shirato H, Asaka M. Chuma M, et al. Among authors: kobayashi t. J Gastroenterol Hepatol. 2011 Jul;26(7):1123-32. doi: 10.1111/j.1440-1746.2011.06745.x. J Gastroenterol Hepatol. 2011. PMID: 21501224
Hepatosplenic gamma-delta T-cell lymphoma associated with Epstein-Barr virus.
Tsunematsu S, Natsuizaka M, Fujita H, Otsuka N, Terashita K, Sato F, Kobayashi T, Nakai M, Tsukuda Y, Horimoto H, Sho T, Suda G, Nakanishi M, Hashino S, Chuma M, Sakamoto N. Tsunematsu S, et al. Among authors: kobayashi t. Intern Med. 2014;53(18):2079-82. doi: 10.2169/internalmedicine.53.2236. Epub 2014 Sep 15. Intern Med. 2014. PMID: 25224191 Free article.
Efficacy and safety of daclatasvir and asunaprevir combination therapy in chronic hemodialysis patients with chronic hepatitis C.
Suda G, Kudo M, Nagasaka A, Furuya K, Yamamoto Y, Kobayashi T, Shinada K, Tateyama M, Konno J, Tsukuda Y, Yamasaki K, Kimura M, Umemura M, Izumi T, Tsunematsu S, Sato F, Terashita K, Nakai M, Horimoto H, Sho T, Natsuizaka M, Morikawa K, Ogawa K, Sakamoto N. Suda G, et al. Among authors: kobayashi t. J Gastroenterol. 2016 Jul;51(7):733-40. doi: 10.1007/s00535-016-1162-8. Epub 2016 Jan 14. J Gastroenterol. 2016. PMID: 26768604 Free article.
Prevalence and characteristics of naturally occurring sofosbuvir resistance-associated variants in patients with hepatitis C virus genotype 1b infection.
Ito J, Suda G, Yamamoto Y, Nagasaka A, Furuya K, Kumagai K, Kikuchi H, Miyagishima T, Kobayashi T, Kimura M, Yamasaki K, Umemura M, Izumi T, Tsunematsu S, Sato F, Tsukuda Y, Terashita K, Nakai M, Sho T, Natsuizaka M, Morikawa K, Ogawa K, Sakamoto N; NORTE Study Group. Ito J, et al. Among authors: kobayashi t. Hepatol Res. 2016 Dec;46(13):1294-1303. doi: 10.1111/hepr.12685. Epub 2016 Apr 8. Hepatol Res. 2016. PMID: 26896756
Safety and efficacy of daclatasvir and asunaprevir in hepatitis C virus-infected patients with renal impairment.
Suda G, Nagasaka A, Yamamoto Y, Furuya K, Kumagai K, Kudo M, Terashita K, Kobayashi T, Tsunematsu I, Yoshida J, Meguro T, Kimura M, Ito J, Umemura M, Izumi T, Tsunematsu S, Sato F, Tsukuda Y, Nakai M, Sho T, Natsuizaka M, Morikawa K, Ogawa K, Sakamoto N; NORTE Study Group. Suda G, et al. Among authors: kobayashi t. Hepatol Res. 2017 Oct;47(11):1127-1136. doi: 10.1111/hepr.12851. Epub 2017 Jan 31. Hepatol Res. 2017. PMID: 27943523
Add-on effects of fluvastatin in simeprevir/pegylated-interferon/ribavirin combination therapy for patients with genotype 1 hepatitis C virus infection: A randomized controlled study.
Suda G, Ito J, Nagasaka A, Yamamoto Y, Furuya K, Okamoto M, Terashita K, Kobayashi T, Tsunematsu I, Yoshida J, Meguro T, Ohara M, Kawagishi N, Kimura M, Umemura M, Izumi T, Tsukuda Y, Nakai M, Sho T, Natsuizaka M, Morikawa K, Ogawa K, Sakamoto N; NORTE Study Group. Suda G, et al. Among authors: kobayashi t. Hepatol Res. 2018 Feb;48(3):E146-E154. doi: 10.1111/hepr.12938. Epub 2017 Aug 10. Hepatol Res. 2018. PMID: 28722780
Safety and efficacy of sofosbuvir and ribavirin for genotype 2 hepatitis C Japanese patients with renal dysfunction.
Sho T, Suda G, Nagasaka A, Yamamoto Y, Furuya K, Kumagai K, Uebayashi M, Terashita K, Kobayashi T, Tsunematsu I, Onodera M, Meguro T, Kimura M, Ito J, Umemura M, Izumi T, Kawagishi N, Ohara M, Ono Y, Nakai M, Natsuizaka M, Morikawa K, Ogawa K, Sakamoto N; NORTE Study Group. Sho T, et al. Among authors: kobayashi t. Hepatol Res. 2018 Jun;48(7):529-538. doi: 10.1111/hepr.13056. Epub 2018 Feb 15. Hepatol Res. 2018. PMID: 29316051
14,904 results
You have reached the last available page of results. Please see the User Guide for more information.